Please login to the form below

Digital therapeutics and their impact on society

Head of Customer Experience Elisa del Galdo explores how healthcare technology can help chronic disease patients and asks what makes a good digital therapeutic?

In the 20th century, research, technology and new novel treatments have enabled us to increase the average lifespan by 25 years, but our healthspan has not increased accordingly. We live longer, but not necessarily better – unfortunately, our quality of life has not improved throughout these added years. This is in part due to the explosive, bordering on unmanageable, increase in chronic diseases, such as cardiovascular disease, diabetes, Alzheimer’s disease, obesity and asthma.

Often these conditions are not experienced in isolation, resulting in many patients managing two or more comorbidities, leading to complex health problems that are more difficult to monitor and manage.

The World Health Organisation reports that by 2020 chronic diseases will account for three-quarters of all deaths worldwide and will reduce the quality of life for patients and their caregivers. With the average cost of managing comorbid chronic patients in the UK estimated to be eight times that of a relatively healthy patient, the economic impact of these illnesses on healthcare systems is immense.

To solve this problem, our systems must be more efficient and more effective in the management and prevention of chronic diseases.

Digital therapeutics, such as smartphone apps and wearable technology, can be used to relieve some of the pressure. They can be used in a multitude of ways to support the effective delivery of healthcare.

This includes monitoring, motivating, changing behaviour, facilitating communication, and helping to manage processes, all while collecting valuable data. When done well, these tools can facilitate more meaningful interactions between patients and healthcare professionals.

DOWNLOAD THE FULL ARTICLE HERE

15th January 2020

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Three strategies for managing loss of exclusivity successfully
Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
What does the future hold for Medical Affairs?
Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
Unpacking rare diseases in the first edition of Delta magazine
Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health